podcasts
Combatting disease with antibody drug conjugates
Tune into this episode where we investigate how antibody drug conjugates can be optimised, as well as the future of the field.
List view / Grid view
Cancer
news
Enhancing drug discovery using genetically diverse mouse models
Researchers suggest that integrating genetically diverse mouse models with cell-based assays will better replicate human diseases.
article
Patient-centred oncology: transforming drug development
As deeper understanding of disease makes the development and commercialisation of oncology drugs more complex, developers are under more pressure than ever to deliver value-based treatments. In this article, Rebecca Goldstein, Senior Principal, Strategic Consulting at Envision Pharma Group, explores anchoring a programme to patient experience as a solution.
news
Reprogramming B cells to produce custom antibodies
The new technique could be adapted to produce a wide range of antibodies to combat chronic conditions like HIV.
article
Restoring TERT to attenuate ageing hallmarks
In this Q&A, Dr Ronald DePinho of MD Anderson elucidates their preclinical proof-of-concept that adjusting TERT levels could be a viable therapeutic approach for mitigating age-related diseases, such as cancer, heart disease and Alzheimer’s.
podcasts
How mRNA technology could revolutionise therapeutics
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
article
Supercharging conventional monoclonal antibodies
In this Q&A, Krishna Polu and Dennis Pedersen, senior leaders of Commit Biologics, which is backed by Novo Holdings and Bioqube Ventures, elucidate how their technology differs from other existing therapeutic platforms and highlight its implications for the treatment of both cancer and autoimmune disease.
article
Translating ‘nature’s cues’ into breakthrough immunotherapies
Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming…
news
Small molecule inducers of trained immunity found
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
article
Liquid biopsy helps advance oncology drug development
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
article
Could illuminating the surfaceome help find new targeted cancer therapies?
At the heart of precision oncology is the need to increase our understanding and knowledge of surface proteins found on tumour cells. Here Roman Thomas, CEO of DISCO Pharmaceuticals, explains how it is using cutting-edge technology to explore the surfaceome – a map of the proteins on the cell’s surface…
news
Discovery of a promising agonist adjuvant
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
news
The potential of deep learning: generating drug targets
Researchers have designed synthetic, soluble versions of cell membrane proteins, which will enable faster and easier screening for new drugs.
news
Mini-colons offer improved cellular diversity, longevity and function
Mini-colons, which closely resemble in vivo tissue, were used for several applications, including the characterisation of anticancer drug toxicity profiles.
news
Cancer dependencies missed by some CRISPR guides
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
